Loading clinical trials...

A Study of GZR18 Injection in Obese/Overweight Patients | Clinical Trials | Clareo Health

COMPLETEDPHASE2

A Study of GZR18 Injection in Obese/Overweight Patients

A Multicenter, Randomized, Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Chinese Obese/Overweight Patients

NCT06256562•Gan and Lee Pharmaceuticals, USA

View on ClinicalTrials.gov

Summary

This study is a multicenter, randomized, placebo-controlled phase II clinical study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of GZR18 injection in Chinese adult obese/overweight subjects.

Eligibility

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Male or female aged 18-75 years (inclusive).
•2. Obese subjects (BMI≥28 kg/m2), Or overweight subjects (24 kg/m2≤BMI\<28 kg/m2) with at least one comorbidity.
•3. Able to understand the procedures and methods in this study; willing and able to maintain a stable diet and exercise lifestyle during the research period, and willing to sign the ICF voluntarily.

Exclusion Criteria

•1. Limb deformities or defects affecting height and body weight measurement.
•2. Pregnant or lactating women, men or women of reproductive potential unwilling to use contraception throughout the study and for 6 months after the last dose of investigational drug.
•3. History of drug abuse within 1 year before screening, or positive results in drug abuse screening during screening or before randomization.
•4. Alcohol abuse history within 6 months prior to screening.
•5. Subjects who are known or suspected to be allergic to GLP-1 drugs or excipients.
•6. Subjects with an absolute weight change greater than 5.0% due to any reason within the 3 months prior to screening.

Locations (1)

Gan & Lee Pharmaceuticals Co., Ltd

Beijing, China

Key Dates

Start Date

June 8, 2023

Primary Completion Date

June 5, 2024

Completion Date

June 5, 2024

Last Updated

October 1, 2025

Enrollment

340

ACTUAL participants

Conditions

ObesityOverweight

Interventions

GZR18

DRUG

Placebo

OTHER

Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System

NCT01143454

Metabolic DiseaseObesity+4 more

View study

RECRUITINGNA

Multi-Acupoint Laser Therapy for Body Shape and Composition in Obese Menopausal Women

NCT07472881

MenopausePerimenopause+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 1, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study of GZR18 Injection in Obese/Overweight Patients

Inclusion Criteria

Exclusion Criteria

Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System

Multi-Acupoint Laser Therapy for Body Shape and Composition in Obese Menopausal Women

Testing an Integrated PTSD and Weight Management Intervention: A Hybrid Type 1 Trial

Variability In Mixed Meal Tests: Fixed Versus Adjusted to Energy Needs Caloric Dose

Protein Supplementation Intervention on Body Weight

iWAIST Trial: ERCG (Endoscopic Radial Compression Gastroplasty) vs Optimized Lifestyle Intervention for Weight Loss